Orasure Technologies’ 2026 Q2 Call: CT/NG Resubmission Costs, Margin Trajectory, and Launch Timelines Clash

Date of Call: Aug 5, 2026

Financials Results

• Revenue: $30.6 million, grew 9.7% on a sequential basis
• Gross Margin: GAAP gross margin increased 120 basis points sequentially to 43.5% from 42.3% in Q1 2026; non-GAAP gross margin increased to 44.2% compared to 43.4%
• Operating Margin: GAAP operating income in Q2 was $5.4 million; non-GAAP operating loss was $14.7 million

Guidance:

• Revenue for Q3 expected to be $29.5 million to $32.5 million.
• Gross margin in Q3 expected to be similar to Q2.

Business Commentary:

Revenue and Margin Growth:

• OraSure Technologies reported total revenue of $30.6 million for Q2 2026, up 9.7% sequentially.
• The company's GAAP gross margin increased by 120 basis points to 43.5% from Q1 2026.
• The revenue growth was attributed to exceeding guidance, while margin expansion was driven by lower scrap and operational efficiencies, partially offset by revenue mix.

FDA Clearances and Product Development:

• OraSure received FDA clearance for the ColiPDX Urine Collection Kit, enabling at-home self-collection for STI testing.
• The company also received FDA emergency use authorization for the OraQuick Ebola 2.0 rapid antigen test.
• These clearances reflect the company's strengths in public health and regulatory capabilities, enhancing its decentralized diagnostic solutions.

International Diagnostics and Partnerships:

• OraSure's international diagnostics progress includes nearshoring and in-country value-added assembly programs for the OraQuick HID self-test.
• SickleScan revenue is growing twice as fast in 2026 compared to 2025.
• This strategic evolution is aimed at addressing critical public health priorities with increasing localization and diversifying the revenue base.

U.S. Diagnostics and Public Health Demand:

• The company observed stronger public health demand in Q2, with U.S. diagnostic revenue higher than international revenue.
• This was driven by customer purchasing patterns tied to fiscal year cycles and the continued importance of HIV testing programs despite federal funding pressures.

Challenges and Adjustments in Regulatory Pathways:

• OraSure's IntelliQuick CTNG test on the Sherlock platform faced a delay in FDA clearance, with the submission withdrawn to incorporate feedback from the agency.
• The company plans to resubmit the test after addressing FDA feedback, with no incremental cash flow impact expected from the adjustment.

Sentiment Analysis:

Overall Tone: Positive

• Call highlights exceeded revenue guidance, expanded gross margins sequentially, advanced innovation milestones (FDA clearances for ColiPDX and OraQuick Ebola 2.0), and confidence in long-term growth strategy. Management stated 'We have positive momentum on multiple fronts' and 'we are creating durable value for shareholders.'

Q&A:

• Question from Mac Etosh (Stevens): Given the CTNG update, how are you thinking about the timing around a resubmission and potential approval? How is that affecting your cost structure?
  Response: Management is confident in the test's performance and plans to resubmit after incorporating FDA feedback; timing details will be shared later. The delay does not change the 2026 growth outlook, and the cost impact is neutral due to a reduced milestone payment offsetting any incremental expenses.

• Question from Mac Etosh (Stevens): Can you speak to what you're seeing in terms of SMS demand from advanced genetic testing labs?
  Response: SMS revenue grew sequentially in Q2 with continued improvement across customer segments, including advanced diagnostic labs and microbiome collections, indicating a recovery post-COVID.

Contradiction Point 1

Financial Impact of CT/NG Resubmission

Contradiction on whether the resubmission will increase cash flow usage.

Mac Etosh (Stevens) - Mac Etosh (Stevens)

2026Q2: The delay does not change the outlook for revenue growth in 2026 or the goal to achieve operating cash flow break-even in 2027. The total cost impact is expected to be lower than previously anticipated, as any incremental costs will be offset by a reduction in contingent milestone payments... - Kerry Eglinton-Manner(CEO) and Ken McGrath(CFO)

Given the CTNG update, what is your outlook on the resubmission timeline, potential approval, and their impact on future cost structures? - Mac Etoch (Stephens)

2026Q2: The resubmission will not increase overall cash flow from operations usage. Any incremental costs will be offset by a reduction in milestone payments... - Ken McGrath(CFO)

Contradiction Point 2

Outlook on Gross Margin Trajectory

The expected timing and drivers for gross margin improvement conflict between quarters.

Mac Etosh (Stevens) - Mac Etosh (Stevens)

2026Q2: The delay does not change the outlook for revenue growth in 2026 or the goal to achieve operating cash flow break-even in 2027. - Ken McGrath(CFO)

Given the CTNG update, how are you planning the timing for resubmission and potential approval, and how will this impact your future cost structure? - Brendan (covering for Patrick Donnelly) (Citi)

2026Q1: The Q2 gross margin is expected to be similar to Q1's strong performance. Sustained improvement will come from operating efficiencies, specifically leveraging consolidated manufacturing facilities and increased production volumes. - Ken McGrath(CFO)

Contradiction Point 3

Financial Impact of CT/NG Test Submission

The expected cost impact of the regulatory delay is presented as less severe than earlier margin pressure from new product launches.

Mac Etosh (Stevens) - Mac Etosh (Stevens)

2026Q2: The total cost impact is expected to be lower than previously anticipated, as any incremental costs will be offset by a reduction in contingent milestone payments... - Ken McGrath(CFO)

How are you thinking about the timing around resubmission and potential approval following the CTNG update, and how will this impact your cost structure moving forward? - Mac Eatock (Stephens)

2026Q1: Both new products (CT/NG test and Colli-Pee device) are expected to be accretive to overall margins in the long term. However, during the initial launch phase, there will be a ramp-up period with lower volumes, which will result in lower initial margins before improving with scale and absorption. - Ken McGrath(CFO)

Contradiction Point 4

R&D Expense Trajectory

Conflicting statements on whether R&D costs will decrease or remain stable post-submission.

Mac Etosh (Stevens) - Mac Etosh (Stevens)

2026Q2: The delay does not change the outlook for revenue growth in 2026 or the goal to achieve operating cash flow break-even in 2027. The total cost impact is expected to be lower than previously anticipated, as any incremental costs will be offset by a reduction in contingent milestone payments. - Kerry Eglinton-Manner(CEO), Ken McGrath(CFO)

How is the CTNG update impacting the timing of resubmission and potential approval, and how will this affect your cost structure moving forward? - Steven Etoch (Stephens)

20260226-2025 Q4: We are anticipating lower R&D expense for the full year compared to 2025, particularly in clinical trials. However, some clinical trial continuation is expected in Q1 to capture additional data supporting performance claims for upcoming launches. Overall, R&D spending will decrease throughout the year. - Kenneth McGrath(CFO)

Contradiction Point 5

Product Launch Timeline Certainty

Shift from acknowledging regulatory uncertainty to expressing confidence in a specific test's performance.

Mac Etosh (Stevens) - Mac Etosh (Stevens)

2026Q2: The company is confident in the performance of the IntelliQuick CT&G test and is working quickly with the FDA on incorporating feedback for a resubmission. - Kerry Eglinton-Manner(CEO)

Given the CTNG update, how are you thinking about the timing for resubmission and potential approval, and how will this impact your cost structure moving forward? - Brendan (Citi, on for Patrick Donnelly)

20260226-2025 Q4: The regulatory review process is uncertain, so providing specific timing would be false precision. - Carrie Eglinton Manner(CEO)